Patent intelligence · US
US 9045541
CD47 antibodies and methods of use thereof
CD47 antibodies and methods of use thereof
Patent details — US 9045541
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 2, 2015
- Expiration
- May 28, 2035
- Applicant
- Inhibrx, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K39/39558
Quick answer
US 9045541 (CD47 antibodies and methods of use thereof) is held by Inhibrx, Inc.. Status: granted. Granted Jun 2, 2015. Expires May 28, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Inhibrx, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K39/39558, A61K45/06, A61P
More from Inhibrx, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12365728
DLL3 single domain antibodies and therapeutic compositions thereof
granted -
US 12331132
Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
granted -
US 12331126
OX40-binding polypeptides and uses thereof
granted -
US 12227584
Multivalent and multispecific OX40-binding fusion proteins
granted -
US 12187804
Multivalent and multispecific 41BB-binding proteins
granted -
US 12084502
CD33-binding polypeptides and uses thereof
granted -
US 12043667
CLEC12a binding polypeptides and uses thereof
granted -
US 12012459
OX40-binding polypeptides and uses thereof
granted
Frequently asked questions
What is US patent 9045541?
US 9045541 (CD47 antibodies and methods of use thereof) is held by Inhibrx, Inc.. Status: granted. Granted Jun 2, 2015. Expires May 28, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9045541?
Inhibrx, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 9045541 expire?
Our index shows an expiration date of May 28, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.